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Itraconazole Suppresses an Elicitation Phase
of a Contact Hypersensitivity Reaction
Urupongsa Ausaneya1, Akira Kawada1 and Yoshinori Aragane1
Contact dermatitis is caused by epicutaneous exposure to environmentally and/or industrially derived allergens.
As the exposure is unavoidable in many instances, therapeutic suppression of allergic inflammation appears to
be of clinical relevance. It was recently reported that itraconazole (ITZ), an anti-fungal agent, may be of
therapeutic importance in allergic skin diseases. Therefore, we were interested in the effect of ITZ on contact
hypersensitivity (CHS). Mice (C3H/HeN or Balb/c) were administered with ITZ orally before sensitization or
challenged with haptens (dinitrofluorobenzene or oxazolone). Consequently, the administration of ITZ before
challenge, but not before sensitization, significantly suppressed the reaction. Intriguingly, ITZ failed to suppress
the irritant dermatitis induced by croton oil or benzalkonium chloride, suggesting that it may affect molecule(s)
rather selectively involved in the elicitation of CHS. To further analyze mechanisms involved, splenic T cells
obtained from sensitized or naive mice were stimulated with plate-bound anti-CD3 in the presence or absence
of ITZ and release of cytokines was tested by ELISA. T cells from hapten-immunized mice produced a significant
amount of IFN-g, which was markedly suppressed by ITZ. Our study demonstrates that ITZ selectively
suppresses the elicitation phase of CHS possibly via downmodulation of IFN-g.
Journal of Investigative Dermatology (2006) 126, 1028–1035. doi:10.1038/sj.jid.5700102; published online 2 March 2006
INTRODUCTION
Contact dermatitis has been regarded as a major problem in
particular for workers dealing with items containing chemical
compounds. This is best exemplified with occupational
contact dermatitis owing to the increased opportunity to
confront contact sensitizers. If diagnosing procedures accu-
rately detect causal allergens whose elimination from daily
life is possible, contact dermatitis may rather be improved
readily. However, in most instances, the detection and
subsequent avoidance of causal antigens is difficult and thus
not practicable. Without antigen avoidance, patients are
mainly treated with topical or sometimes systemic steroids,
which may be effective to ameliorate ongoing allergic
inflammation on the one hand, but the long-term use of
steroids may lower threshold of the onset of local and/or
systemic adverse effects. Similarly to contact dermatitis,
eczematous dermatoses or atopic dermatitis may in part be
attributed to chronic exposure to environmental allergens
such as house dusts or mites. Avoidance of causal allergens is
one of the emphasized therapeutic suggestions, which,
however, is not practicable in the majority of cases. The
pathogenesis of above referred disorders can be attributed to
elicitation phases of various types (i.e. acute versus chronic
exposure to allergens) of contact hypersensitivity (CHS),
which is a T-cell-mediated cutaneous immune/inflammatory
reaction to antigens. Hence, development of novel therapeu-
tic strategies suitable to better control underlying CHS, in
particular its elicitation phase, should be a major challenge
for clinical dermatologists.
Itraconazole (ITZ) is an anti-fungal triazole compound,
which inhibits cytochrome P-450 that catalyzes the ergosterol
synthesis, an essential component for their cell membrane,
thereby being capable of inhibiting fungal growth (Zucker-
man and Tunkel, 1994; Haria et al., 1996). In addition to the
anti-fungal activity, it has been reported to exert the anti-
inflammatory potential. It is worth noting that other than
dermatophyte-induced dermatoses, ITZ has therapeutic
benefit on amicrobial palmoplantar pustulosis (Mihara
et al., 1998), seborrheic dermatitis (Hay and Graham-Brown,
1997), and atopic dermatitis (Kolmer et al., 1996; Ikezawa
et al., 2004). The reason for its therapeutic usefulness may be
through the reduction of fungi colonies (Malassezia, Candida,
etc.) on the lesions, although a direct link between fungal
infection and the occurrence of these allergic dermatoses is
still missing. Alternatively, it is possible that ITZ may possess
anti-inflammatory properties irrespective of regional coloni-
zation of fungi. In this context, it is noteworthy that ITZ has
been shown to suppress production of type 2 cytokines, IL-4
and IL-5, in anti-CD3 plus anti-CD28-stimulated T cells
obtained from patients with atopic dermatitis (Kanda et al.,
2001). This is the first and direct proof that ITZ modifies
immune cascades unrelated to fungi. However, no evidence
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is so far available demonstrating how ITZ actually controls
allergic inflammation in vivo.
Here, we demonstrate for the first time ITZ-induced
suppression of CHS. Interestingly, it only suppressed the
elicitation phase of CHS, whereas irritant dermatitis was not
affected. This discrepancy may be attributed to the produc-
tion of a type 1 cytokine, IFN-g, since production of this
cytokine from hapten-immunized T cells was significantly
downmodulated by ITZ. This is the first in vivo demonstration
that ITZ exerts anti-inflammatory properties by the suppres-
sion of the elicitation phase of allergic CHS possibly via
inhibition of IFN-g production from hapten-immunized
effector T cells.
RESULTS
Oral administration of ITZ did not affect the induction of CHS
To first analyze the effect of ITZ on CHS, mice (Balb/c or
C3H/HeN) were orally administered with 2 mg/kg ITZ daily
for 3 successive days (day 3 to 1) and sensitized with
DNFB or oxazolone (OX) at day 0. Five days later, mice were
challenged with the respective hapten on the left ears, and
24 hours later, CHS was monitored. As shown in Figure 1a,
oral administration of ITZ did not affect the outcome of an ear
swelling response. The impairment of sensitization of CHS
may lead to the long-lasting immune unresponsiveness,
called tolerance (Toews et al., 1980). Therefore, to check
whether ITZ affect tolerance induction of CHS, ITZ-adminis-
tered animals that were subsequently sensitized and chal-
lenged were left untreated for 14 days, resensitized with the
respective hapten, and 5 days later, mice were rechallenged.
Consequently, all the animals showed vigorous CHS regard-
less of the types of haptens or of mouse strains (Figure 1b).
Together, these findings clearly indicate that the oral
administration of ITZ neither resulted in the impairment of
the induction of CHS nor led to the development of tolerance.
Oral administration of ITZ inhibits the elicitation phase of CHS
We next checked whether the oral administration of ITZ
affects the elicitation phase of CHS. To do so, mice were first
sensitized with DNFB, and graded doses of ITZ were given
orally to mice daily for 3 successive days before challenge.
Unlike its administration before sensitization, the elicitation
phase of CHS of C3H/HeN was significantly inhibited by the
oral administration of ITZ in a dose-dependent manner
(Figure 2a). Not only C3H/HeN but also Balb/c showed
significant reduction of an ear swelling reaction when ITZ
was administered before challenge with DNFB (Figure 2b).
To see if the suppression of the elicitation phase of CHS by
ITZ is unique for DNFB, OX was used instead of DNFB and
the same procedures were repeated. ITZ suppressed the
elicitation of CHS induced by OX in a dose-dependent
manner in C3H/HeN (Figure 2c) or Balb/c (Figure 2d). Ten
microliters of ITZ orally administered is almost equivalent to
those given to human, considering that 100 mg of ITZ is
applied to a person weighting 50 kg (2 mg/kg per day).
Furthermore, even when the same amounts of ITZ was
applied orally only once before challenge, the inhibition of
CHS was also observed, but to a lesser extent (data not
shown). Therefore, we used throughout this study the oral
administration daily for 3 successive days. Together, these
observations showed that ITZ downmodulated the elicitation
of CHS and this phenomenon may be common regardless of
the kind of antigen.
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Figure 1. ITZ neither inhibited the induction phase of CHS nor led to
tolerance. (a) Mice (C3H/HeN or Balb/c) were first administered orally with
10ml ITZ solution (2 mg/kg) daily for 3 successive days (day 3 to 1) and
sensitized with the indicated hapten on day 0. Five days later, left ear was
challenged with the respective hapten, and CHS was monitored 24 hours
later. (b) Mice treated as in (a) were left untreated for 14 days and resensitized
thereafter with the indicated hapten. Five days later, rechallenge was
performed by painting with the respective hapten on the right ear, and
24 hours later, ear swelling was quantified. Mice challenged without prior
sensitization (negative control) did not show a significant ear swelling
response (1.270.5mm2) (data not shown). CHS was determined as the
amount of swelling of the hapten-challenged ear compared with the thickness
of the vehicle-treated ear in sensitized animals and expressed in milli-
meters 102 (mean7SD). DNFB, dinitrofluorobenzene; OX, oxazolone;
NS, statistically not significant.
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We also examined the effects of ketconazole (KTZ) and
terbinafine (TBF) on the elicitation phase (Figure 3a–d). KTZ,
similarly as ITZ, suppressed the elicitation phase regardless of
mouse strains and sensitizers, whereas TBF failed to do so
(Figure 3a–d).
Histopathological examinations revealed that in DNFB-
challenged ear of C3H/HeN, there is an increased number of
leukocytic infiltration and marked dermal edema (Figure 4b),
whereas ITZ administration before challenge resulted in the
inhibition of ear swelling response (Figure 4c), which was
comparable to that of vehicle-treated mice (Figure 4a). The
same applied for Balb/c mice that showed marked leukocytic
infiltration and dermal edema upon challenge (Figure 4e),
less infiltration when ITZ administration was combined
before challenge (Figure 4f), and no infiltration in vehicle-
treated mice (Figure 4d). These histological findings further
confirmed those of the CHS data (Figure 2).
ITZ failed to suppress the irritant dermatitis
To see if ITZ has an anti-inflammatory effect on non-
immunological irritant dermatitis, mice administered with
ITZ daily for 3 successive days were painted with croton oil
or benzalkonium chloride, and 8 hours later, ear swelling was
monitored. ITZ failed to inhibit irritant dermatitis regardless of
the kind of irritant or of mouse strains (Figure 5).
ITZ suppresses anti-CD3-induced cytokine production by
DNFB-immunized T cells
To analyze the mechanisms underlying ITZ-induced inhibit-
ion of CHS, we next checked its effect on the production of
cytokines. To do so, T cells isolated from spleens and
superficial regional lymph nodes were incubated with graded
doses of ITZ (0, 100, and 1,000 ng/ml) for 15 minutes and
then cultured on anti-CD3e-coated plastic dishes for
16 hours. Based on the manufacturer’s instruction, the
maximal serum concentrations (Cmax) of an active metabolite
of ITZ are 145.2743.8, 267.4771.4, and 678.6762.4 ng/ml
when administered only once with 50, 100, and 200 mg ITZ,
respectively. Therefore, the concentration we used here were
clinically relevant. Stimulation of T cells with anti-CD3e
markedly induced production of IFN-g in DNFB-immunized
T cells, whereas non-sensitized T cells produced only
negligible amount of this cytokine in response to anti-CD3e
(Figure 6a). In addition, T cell production of IL-4 (Figure 6b)
and tumor necrosis factor-alpha (TNF-a) (Figure 6c)
by DNFB-immunized T cells was modestly enhanced by
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Figure 2. ITZ prevented the elicitation phase of CHS. C3H/HeN (a and c) or Balb/c (b and d) were first sensitized against DNFB (a and b) or OX (c and d) on day
0 and administered orally with the indicated dose of ITZ (10 ml ITZ solution corresponded 2 mg/kg ITZ) daily for 3 successive days (days 2–4) and challenged the
left ear with the indicated hapten on day 5. Twenty-four hours later, CHS was monitored as in Figure 1. NS¼ statistically not significant; *Po0.05, **Po0.01.
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anti-CD3e, although the grade of the induction of the latter
two cytokines were absolutely less than that of IFN-g. This
may indicate that the immunized T cells were skewed to
produce a type 1 cytokine, IFN-g. Interestingly, production of
IFN-gwas inhibited even in the presence of a subclinical dose
of ITZ (100 ng/ml), which was more markedly inhibited with
1,000 ng/ml ITZ (Figure 6a). In addition, the same tendency
was also seen in case of IL-4 production (Figure 6b), although
TNF-a production was only suppressed upon treatment with
1,000 ng/ml ITZ (Figure 6c).
DISCUSSION
Here, we analyzed the effect of ITZ on a CHS reaction. To
address this question, mice were first orally administered with
various amounts of ITZ daily for 3 successive days and
sensitized against haptens (DNFB, OX) 24 hours later As
shown in Figure 1, ITZ administration before sensitization
neither affect CHS nor led to long-lasting immune unrespon-
siveness called tolerance. By contrast, ITZ, when applied
before challenge, significantly ameliorated CHS (Figure 2).
Interestingly, oral administration of KTZ, but not TBF, before
challenge also resulted in the suppression of the elicitation of
CHS. Since both ITZ and KTZ belong to an azole group of
anti-dermatophytes, suppressive activity on the elicitation
may be a common phenomenon of this type of drug. This
indicates that ITZ does not affect host’s immunization to
specific antigens, but rather suppressed inflammatory reac-
tions, as inflammatory processes might also be delineated
depending on the time points. Upon epicutaneous antigen
application at the time of elicitation, local antigen-presenting
cells (i.e. epidermal Langerhans cells) present processed
antigenic peptides on major histocompatibility complex class
I or class II, leading to the activation of hapten-immunized
cells, which are currently referred to as IFN-g-producing
CD8þ T cells (Tc1) in an antigen-specific manner (Xu et al.,
1996). Activation of Tc1 effector cells subsequently activates
the production of various cytokines in local milieu, and
finally pathological changes (intradermal edema, spongiosis
of epidermal layer) are developed. In this scenario, the early
phase leads to clonal expansion of effector T cells and thus is
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Figure 3. KTZ, but not TBF, also interfered with the elicitation phase of CHS. C3H/HeN (a and c) or Balb/c (b and d) were first sensitized against DNFB (a and
b) or OX (c and d) on day 0 and administered orally with the indicated dose of ITZ (10 ml ITZ solution corresponded 2 mg/kg ITZ), 20 ml KTZ (4 mg/kg), or 25 ml
TBF (5 mg/kg) daily for 3 successive days (days 2–4) and challenged the left ear with the indicated hapten on day 5. Twenty-four hours, later, CHS was monitored
as in Figure 1. NS¼ statistically not significant; *Po0.01.
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restricted to specific antigen, but the later stage may be
antigen-independent amplification step of inflammation.
Hence, we next checked which component of the elicitation
phase of CHS was suppressed by ITZ. To do so, we chose to
use irritant dermatitis as a model since it is a non-
immunological skin inflammation following the application
of irritants; we can distinguish whether its effect is on an
antigen-specific early elicitation phase or a late nonspecific
inflammation. Accordingly, mice were first given oral ITZ
daily for 3 successive days, and the next day, CHS was
evaluated 8 hours after painting with irritants (croton oil or
benzalkonium chloride). Surprisingly, ITZ failed to amelio-
rate irritant dermatitis, indicating that it might inhibit the early
elicitation phase that is rather specific for allergic CHS.
Although there is evidence that cytokines, especially IL-1b
(Enk and Katz, 1992; Enk et al. 1993), may contribute to the
induction phase of CHS, little is known about immunological
mechanisms of its elicitation phase (Piquet et al., 1991; Dieli
et al., 1994; Salerno et al., 1995). In this context, however, it
was reported that in an elicitation phase of CHS, CD8þ
T cells act as effector T cells, which contribute to make final
pathological changes, whereas CD4þ T cells help CD8þ
T cells to complete the reaction (Bour et al., 1995; Wang
et al., 2000). Furthermore, as mentioned earlier, IFN-g-
producing CD8þ T cells (Tc1) play a major role in an
elicitation phase (Xu et al., 1996). Based on these notions, we
were interested how ITZ may interfere with effector T cells in
this event. To address this issue, T cells obtained from either
naive or DNFB-sensitized animals were cultured on plastic
dishes, which were pre-coated with anti-CD3 in the presence
or absence of graded amounts of ITZ, and finally cytokine
ELISA was performed. Anti-CD3 stimulation mimics TCR-
delivered intracellular signaling and thereby enables us to
evaluate cytokine production of in vivo-immunized T cells
when compared to a cytokine profile of naive T cells.
Supernatants were collected 48 hours later, and finally the
level of cytokines released was determined by sandwich
ELISA specific for IL-4, TNF-a, or IFN-g. Consequently, it was
found that in vivo-immunized T cells produced a significantly
higher amount of IFN-g as compared to naive T cells, whereas
IL-4 and TNF-a was only slightly increased in immunized
cells (Figure 6). This indicates that immunized T cells
preferentially produced type 1 cytokine (IFN-g). Interestingly,
production of IFN-g was markedly prevented by ITZ
(Figure 6). Since IFN-g-producing effector T cells are believed
to actively be involved in the elicitation phase of CHS, the
suppression of cytokine production by ITZ might be rational
for the ability to suppress the elicitation phase. Furthermore,
this prediction may be supported by the observation by Dieli
et al. (1997) showing that a neutralizing antibody directed
against IFN-g inhibited CHS when it was injected intra-
venously before challenge, but not sensitization. Moreover,
regarding the involvement of IFN-g in the elicitation phase,
Asada et al. (1997) showed interesting observations. Briefly,
with hapten, trinitrochlorobenzene, they challenged mouse
ear that were either hapten sensitized or left unsensitized
before. The subsequently performed quantitative PCR re-
vealed upregulated expression of mRNA specific for IFN-g,
a b
c d
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Figure 4. Histological findings. C3H/HeN were first (b, c) sensitized or (a)
left unsensitized against DNFB on day 0 and (c) administered orally with 10 ml
ITZ solution (2 mg/kg) daily for 3 successive days (days 2–4) and (a–c) painted
the left ear with the indicated hapten on day 5. Balb/c were treated in the
same manner in the (d) presence or the (e) absence of 2 mg/kg ITZ. Twenty-
four hours later, the hapten-painted ear was cut, fixed in formaldehyde,
sectioned, stained with hematoxylin–eosin, and microscopically observed.
Original magnification: (a–c)  40, (d, e)  200.
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Figure 5. ITZ did not affect irritant dermatitis. C3H/HeN or Balb/c were first
administered orally with 10 ml ITZ solution (2 mg/kg) daily for 3 successive
days (day 3 to 1) or left untreated, and painted with irritant, benzalkonium
chloride, or croton oil on day 0 as indicated in the figure. Eight hours later, ear
swelling responses were monitored as in Figure 1. NS, statistically not
significant.
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IL-1b, IL-2, IL-12 p40, IL-4, and IL-10 in the epidermis and
dermis upon challenge. Interestingly, among these cytokines,
only mRNA for IL-4 and IFN-g were markedly upregulated
upon challenge following sensitization, whereas all others
were upmodulated even without sensitization. This indicates
that regulation of IFN-g seems specific for the elicitation of
CHS. Collectively, these observations show the significance
of IFN-g in the elicitation phase of CHS, thereby implying that
in our experimental setting, ITZ through the suppression of
IFN-g production may inhibit the elicitation of CHS.
However, it still remains unclear whether ITZ down-
regulates the production of IFN-g from effector T cells or
reduces the numbers (frequency) of effector T cells. This is an
interesting question, which needs further analysis. Further-
more, it has been currently reported that ITZ is effective in
blocking cellular cytochrome P-450 on a murine endothelial
cell line, and that TNF-a induced expression of adhesion
molecules, such as E-selectin, intercellular adhesion mole-
cule-1, mucosal addressin cell adhesion molecule, and
vascular cellular adhesion molecule-1 is cytochrome P-450
dependent (Sasaki et al., 2002). Therefore, it might be
possible that ITZ is able to suppress migration of leukocytes
to inflammatory milieu, possibly giving an alternative
explanation of how ITZ suppresses the elicitation phase.
As mentioned earlier, ITZ may be therapeutically bene-
ficial in treating various inflammatory dermatoses. This may,
at least in part, be attributed to the suppression of elicitation
of allergic pathways possibly via functional modulation of
cytokine production of effector T cells, such as IFN-g.
MATERIALS AND METHODS
Reagents
ITZ and KTZ are kind gifts from Janssen Research Foundation
(Beerse, Belgium). TBF was obtained from Novartis Pharma (Basel,
Switzerland). The kits of ELISA specific for IL-4, IFN-g, and TNF-a
were purchased from R&D systems (Minneapolis, MN).
Contact hypersensitivity
All animal experiments in this paper were performed under a
protocol approved by the Institutional Review Board of Kinki
University School of Medicine. C3H/HeN or Balb/c mice (8–10
weeks old) were obtained from Japan Clea (Hamamatsu, Japan).
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Figure 6. ELISA assay. C3H/HeN were sensitized against DNFB or left untreated. Five days later, T cells were isolated from spleens and superficial regional
lymph nodes, which were pretreated with the indicated concentration of ITZ for 15 minutes and then cultured on 96-well plates pre-coated with anti-CD3e.
Sixteen hours later, the culture supernatants were collected and applied to cytokine ELISA specific for (a) IFN-g, (b) IL-4, and (c)TNF-a. The experiments were
repeated twice and the results shown are one of the representatives. NS, statistically not significant; *Po0.05; **Po0.01.
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Mice were sensitized by painting with 25 ml of 0.5% DNFB (Sigma
Corp., St Louis, MO) solution (acetone:olive oil, 4:1) onto the shaved
back on day 0 as reported previously (Schwarz et al., 1993). On day
5, the left ear was challenged by painting with 20ml of 0.3% DNFB.
The right ear was painted with vehicle alone. Ear swelling was
quantified 24 hours later using a spring-loaded micrometer. CHS was
determined as the amount of swelling of the hapten-challenged ear
compared with the thickness of the vehicle-treated ear in sensitized
animals and expressed in millimeters 102 (mean7SD). Negative
controls consisted of mice that were ear challenged without prior
sensitization. In some experiments, OX (Sigma) was used (25 ml 0.8%
for sensitization and 20 ml 0.3% for challenge). For some purposes,
ITZ-administered mice conducted with hapten sensitization and
challenge were resensitized through untreated abdominal skin 2
weeks later and rechallenged on the right ear 5 days thereafter. Each
group consisted of at least seven mice. Each experiment was
performed at least three times. Data were analyzed by Student’s
t-test, and differences were considered as significant at Po0.05.
Irritant dermatitis
To induce irritant dermatitis, 20 ml of 1% croton oil (Sigma) dissolved
in acetone were applied on the left ear. Ear swelling was measured
8 hours after application of the irritant with a spring-loaded
micrometer. The irritant reaction was determined as the amount of
swelling of the irritant-treated left ear compared to the thickness of
the vehicle (acetone)-treated right ear and expressed in milli-
meters 102. As a further irritant, benzalkonium chloride (Sigma)
was used, which was dissolved in acetone at a concentration of 5%.
The irritant application and measurement was performed as with
croton oil.
Administration of anti-fungal agents
ITZ, KTZ, and TBF were first dissolved in DMSO and then suspended
in milk solution. Mice were given various amounts of ITZ solution for
3 successive days either before sensitization or before challenge. In
case of KTZ and TBF, a dose of 4 and 5 mg/kg, respectively, was
corresponding to physiological serum concentration and orally
administered. Similarly, administration with 10 ml of the ITZ solution
was calculated as 2 mg/kg, almost equivalent to an orally applied
dose of ITZ for patients having nail involvements with tricophytons.
Splenic lymphocytes preparation and determination of cytokine
production
Splenic T cells were obtained through density-gradient centrifuga-
tion with Ficoll-Paque Pluss (Amersham Biosciences, Uppsala,
Sweden) from blood cells of spleens and superficial lymph nodes.
Splenocytes were first reacted with the graded concentration of ITZ
(0, 100, and 1,000 ng/ml) and stimulated with plate-bound hamster
monoclonal IgG1 directed against mouse CD3e (145.2C11; BD
Pharmingen, San Jose, CA) essentially following an earlier report
(Engeman et al., 2000) with slight modifications. Briefly, the 96-well
U-bottom tissue culture plates were pre-coated with 30 ml/well anti-
CD3e antibody, or as negative control, pre-immune hamster serum
for 90 min at 371C, and then washed extensively. Splenic T cells
were obtained from non-sensitized and hapten-sensitized mice on
day 5, suspended in complete medium (Roswell Park Memorial
Institute 1640 supplemented with 5% fetal bovine serum, 1%
L-glutamine, 1% antibiotics/anti-mycotic solution; all purchased
from Gibco BRL, Rockville, MD), and 2 105 T cells from each
group were delivered to each well in 200ml complete medium. After
48 hours, culture supernatant was harvested, filtered through a 0.2-
mm micropore filter to exclude cell debris, and assayed for cytokine
production by ELISA specific for IL-2, IFN-g, IL-4, and TNF-a (all
purchased from R&D Systems). Each experiment was performed
three times, and a single representative result was shown in the
‘Result’ section.
Histology
The ear was fixed in buffered formaldehyde, embedded in paraffin,
sectioned, and stained with hematoxylin–eosin. The samples were
observed and evaluated under light microscope.
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